Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from AC Immune SA ( (ACIU) ) is now available.
On September 4, 2025, AC Immune SA announced a strategic shift to focus on its key assets, including three clinical-stage active immunotherapy programs and promising small molecule programs targeting NLRP3 and Tau. This decision, following an executive management review, involves a 30% workforce reduction and is expected to extend the company’s cash runway to the end of Q3 2027. The move aims to enhance operational efficiency and maintain progress on clinical milestones, while also supporting affected employees through severance packages and job-seeking assistance.
The most recent analyst rating on (ACIU) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
AC Immune SA’s stock score is primarily influenced by its financial performance and technical analysis. While the company shows potential with improving cash flow and short-term bullish momentum, persistent net losses and a negative P/E ratio weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company utilizes its SupraAntigen® and Morphomer® technology platforms to develop a diversified pipeline of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has established strategic partnerships with major pharmaceutical companies, securing substantial non-dilutive funding and potential milestone payments exceeding $4.5 billion.
Average Trading Volume: 139,776
Technical Sentiment Signal: Sell
Current Market Cap: $218.7M
For detailed information about ACIU stock, go to TipRanks’ Stock Analysis page.